Vanku

Azacitidine at 75 mg/m was administered both intravenously or subcutaneously on Days 1-7 of every 28-day cycle beginning on Cycle 1 Day 1. Injections sites could put sufferers in danger for hematomas and result in infection. Eye poking is particularly concerning; it happens more frequently amongst y...